Immune Complexes in ovarian carcinoma
Immunodiagnostic screening may improve the survival of ovarian carcinoma by earlier detection and follow-up during treatment. Presently, several ovarian cancer-associated antigens are being utilized to monitor treatment response; a specific and precise test for screening is not currently available....
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 1989-03, Vol.32 (3), p.350-353 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 353 |
|---|---|
| container_issue | 3 |
| container_start_page | 350 |
| container_title | Gynecologic oncology |
| container_volume | 32 |
| creator | Runowicz, Carolyn D. Cohen, Carmel J. Adelsberg, Bernard R. |
| description | Immunodiagnostic screening may improve the survival of ovarian carcinoma by earlier detection and follow-up during treatment. Presently, several ovarian cancer-associated antigens are being utilized to monitor treatment response; a specific and precise test for screening is not currently available. The present study was designed to investigate the presence and clinical significance of circulating immune complexes (IC) in patients with ovarian carcinoma using a polyethylene glycol (PEG) assay. If this assay were to prove clinically useful in patients with ovarian carcinoma, its potential as a screening test would then be evaluated. Serum was obtained from 38 patients with advanced ovarian carcinoma preoperatively, postoperatively, and prior to the administration of a combination chemotherapy regimen containing cisplatin. Five patients had values ⩾0.10. This test identified only 12.5% of the patients with active disease. Serial sampling failed to reveal any correlation with disease status. Our experience does not support the usefulness of IC levels in studying or treating patients with ovarian carcinoma. |
| doi_str_mv | 10.1016/0090-8258(89)90638-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78864712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0090825889906380</els_id><sourcerecordid>78864712</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-e053acc7b275ab2f0f4cd01481b35ef6a0a3eec929e946995e46fd53309570213</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotVb_gUIXKroYvUkmmWQjSPFRKLjRdchk7kBkHjXpFP33ztihS1d3cb5zOPcQck7hjgKV9wAaEsWEulH6VoPkKoEDMqWgRSKV0IdkukeOyUmMnwDAgbIJmTDNekxOydWyrrsG54u2Xlf4jXHum3m7tcHbZu5scL5pa3tKjkpbRTwb74x8PD-9L16T1dvLcvG4ShxXcpMgCG6dy3KWCZuzEsrUFUBTRXMusJQWLEd0mmnUqdRaYCrLQnDed8mAUT4j17vcdWi_OowbU_vosKpsg20XTaaUTDPKejDdgS60MQYszTr42oYfQ8EM65jhdTO8bpQ2f-sY6G0XY36X11jsTeMcvX456jY6W5XBNs7HPZYx4FQPMQ87DPstth6Dic5j47DwAd3GFK3_v8cv85J-cQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78864712</pqid></control><display><type>article</type><title>Immune Complexes in ovarian carcinoma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Runowicz, Carolyn D. ; Cohen, Carmel J. ; Adelsberg, Bernard R.</creator><creatorcontrib>Runowicz, Carolyn D. ; Cohen, Carmel J. ; Adelsberg, Bernard R.</creatorcontrib><description>Immunodiagnostic screening may improve the survival of ovarian carcinoma by earlier detection and follow-up during treatment. Presently, several ovarian cancer-associated antigens are being utilized to monitor treatment response; a specific and precise test for screening is not currently available. The present study was designed to investigate the presence and clinical significance of circulating immune complexes (IC) in patients with ovarian carcinoma using a polyethylene glycol (PEG) assay. If this assay were to prove clinically useful in patients with ovarian carcinoma, its potential as a screening test would then be evaluated. Serum was obtained from 38 patients with advanced ovarian carcinoma preoperatively, postoperatively, and prior to the administration of a combination chemotherapy regimen containing cisplatin. Five patients had values ⩾0.10. This test identified only 12.5% of the patients with active disease. Serial sampling failed to reveal any correlation with disease status. Our experience does not support the usefulness of IC levels in studying or treating patients with ovarian carcinoma.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/0090-8258(89)90638-0</identifier><identifier>PMID: 2920956</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adult ; Aged ; Antigen-Antibody Complex - analysis ; Biological and medical sciences ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Middle Aged ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - immunology ; Ovarian Neoplasms - therapy ; Polyethylene Glycols ; Precipitin Tests ; Prognosis ; Tumors</subject><ispartof>Gynecologic oncology, 1989-03, Vol.32 (3), p.350-353</ispartof><rights>1989</rights><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-e053acc7b275ab2f0f4cd01481b35ef6a0a3eec929e946995e46fd53309570213</citedby><cites>FETCH-LOGICAL-c386t-e053acc7b275ab2f0f4cd01481b35ef6a0a3eec929e946995e46fd53309570213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0090-8258(89)90638-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7203190$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2920956$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Runowicz, Carolyn D.</creatorcontrib><creatorcontrib>Cohen, Carmel J.</creatorcontrib><creatorcontrib>Adelsberg, Bernard R.</creatorcontrib><title>Immune Complexes in ovarian carcinoma</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Immunodiagnostic screening may improve the survival of ovarian carcinoma by earlier detection and follow-up during treatment. Presently, several ovarian cancer-associated antigens are being utilized to monitor treatment response; a specific and precise test for screening is not currently available. The present study was designed to investigate the presence and clinical significance of circulating immune complexes (IC) in patients with ovarian carcinoma using a polyethylene glycol (PEG) assay. If this assay were to prove clinically useful in patients with ovarian carcinoma, its potential as a screening test would then be evaluated. Serum was obtained from 38 patients with advanced ovarian carcinoma preoperatively, postoperatively, and prior to the administration of a combination chemotherapy regimen containing cisplatin. Five patients had values ⩾0.10. This test identified only 12.5% of the patients with active disease. Serial sampling failed to reveal any correlation with disease status. Our experience does not support the usefulness of IC levels in studying or treating patients with ovarian carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigen-Antibody Complex - analysis</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Polyethylene Glycols</subject><subject>Precipitin Tests</subject><subject>Prognosis</subject><subject>Tumors</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLAzEUhYMotVb_gUIXKroYvUkmmWQjSPFRKLjRdchk7kBkHjXpFP33ztihS1d3cb5zOPcQck7hjgKV9wAaEsWEulH6VoPkKoEDMqWgRSKV0IdkukeOyUmMnwDAgbIJmTDNekxOydWyrrsG54u2Xlf4jXHum3m7tcHbZu5scL5pa3tKjkpbRTwb74x8PD-9L16T1dvLcvG4ShxXcpMgCG6dy3KWCZuzEsrUFUBTRXMusJQWLEd0mmnUqdRaYCrLQnDed8mAUT4j17vcdWi_OowbU_vosKpsg20XTaaUTDPKejDdgS60MQYszTr42oYfQ8EM65jhdTO8bpQ2f-sY6G0XY36X11jsTeMcvX456jY6W5XBNs7HPZYx4FQPMQ87DPstth6Dic5j47DwAd3GFK3_v8cv85J-cQ</recordid><startdate>19890301</startdate><enddate>19890301</enddate><creator>Runowicz, Carolyn D.</creator><creator>Cohen, Carmel J.</creator><creator>Adelsberg, Bernard R.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890301</creationdate><title>Immune Complexes in ovarian carcinoma</title><author>Runowicz, Carolyn D. ; Cohen, Carmel J. ; Adelsberg, Bernard R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-e053acc7b275ab2f0f4cd01481b35ef6a0a3eec929e946995e46fd53309570213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigen-Antibody Complex - analysis</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Polyethylene Glycols</topic><topic>Precipitin Tests</topic><topic>Prognosis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Runowicz, Carolyn D.</creatorcontrib><creatorcontrib>Cohen, Carmel J.</creatorcontrib><creatorcontrib>Adelsberg, Bernard R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Runowicz, Carolyn D.</au><au>Cohen, Carmel J.</au><au>Adelsberg, Bernard R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune Complexes in ovarian carcinoma</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1989-03-01</date><risdate>1989</risdate><volume>32</volume><issue>3</issue><spage>350</spage><epage>353</epage><pages>350-353</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>Immunodiagnostic screening may improve the survival of ovarian carcinoma by earlier detection and follow-up during treatment. Presently, several ovarian cancer-associated antigens are being utilized to monitor treatment response; a specific and precise test for screening is not currently available. The present study was designed to investigate the presence and clinical significance of circulating immune complexes (IC) in patients with ovarian carcinoma using a polyethylene glycol (PEG) assay. If this assay were to prove clinically useful in patients with ovarian carcinoma, its potential as a screening test would then be evaluated. Serum was obtained from 38 patients with advanced ovarian carcinoma preoperatively, postoperatively, and prior to the administration of a combination chemotherapy regimen containing cisplatin. Five patients had values ⩾0.10. This test identified only 12.5% of the patients with active disease. Serial sampling failed to reveal any correlation with disease status. Our experience does not support the usefulness of IC levels in studying or treating patients with ovarian carcinoma.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>2920956</pmid><doi>10.1016/0090-8258(89)90638-0</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 1989-03, Vol.32 (3), p.350-353 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78864712 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Antigen-Antibody Complex - analysis Biological and medical sciences Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Ovarian Neoplasms - diagnosis Ovarian Neoplasms - immunology Ovarian Neoplasms - therapy Polyethylene Glycols Precipitin Tests Prognosis Tumors |
| title | Immune Complexes in ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A31%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20Complexes%20in%20ovarian%20carcinoma&rft.jtitle=Gynecologic%20oncology&rft.au=Runowicz,%20Carolyn%20D.&rft.date=1989-03-01&rft.volume=32&rft.issue=3&rft.spage=350&rft.epage=353&rft.pages=350-353&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1016/0090-8258(89)90638-0&rft_dat=%3Cproquest_cross%3E78864712%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78864712&rft_id=info:pmid/2920956&rft_els_id=0090825889906380&rfr_iscdi=true |